Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice

Journal of Clinical Hypertension

Volumn 12, Issue 6, 2010, Pages 396-406

  Neutel, Joel M ^a   Eaddy, Michael ^b   Lunacsek, Orsolya E ^b   Roberts, Craig ^c   Chen, Linda ^c   Kean, Allison J ^c   Jackson, James H ^b  

^a Orange County Research Center   (United States)

^b XCENDA   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION;

AMLODIPINE; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY ARTERY DISEASE; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HEALTH RECORDS, PERSONAL; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PROGNOSIS; PYRROLES; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 77954158535     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00290.x     Document Type: Article

References (36)

1. Lloyd-Jones D, Adams R, Carnethon M. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):e21-e181.
2. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000, 14(2):83-90.
3. Wong ND, Lopez VA, L'Italien G. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007, 167(22):2431-2436.
4. Hyre AD, Muntner P, Menke A. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007, 17(7):548-555.
5. Wong ND, Lopez V, Tang S. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol 2006, 98(2):204-208.
6. Chapman RH, Benner JS, Petrilla AA. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005, 165(10):1147-1152.
7. Flack JM, Victor R, Watson K. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 2008, 83(1):35-45.
8. Heisler M, Hogan MM, Hofer TP. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation 2008, 117(22):2884-2892.
9. Ogedegbe G. Barriers to optimal hypertension control. J Clin Hypertens (Greenwich) 2008, 10(8):644-646.
10. Moser M. Physician or clinical inertia: what is it? Is it really a problem? And what can be done about it? J Clin Hypertens (Greenwich) 2009, 11(1):1-4.
11. Bangalore S, Kamalakkannan G, Parkar S. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120(8):713-719.
12. Patel BV, Leslie RS, Thiebaud P. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008, 4(3):673-681.
13. Neutel JM, Bestermann WH, Dyess EM. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 2009, 11:22-30.
14. Grimm R, Malik M, Yunis C. The critical importance of treating absolute cardiovascular risk as opposed to individual cardiovascular risk factors in isolation. J Clin Hypertens 2009, 4(Suppl A):A120-A121.
15. Blank R, LaSalle J, Reeves R. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin GEMINI study). J Clin Hypertens (Greenwich) 2005, 7(5):264-273.
16. Erdine S, Ro YM, Tse H-F. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the GEMINI-AALA study). J Hum Hypertens 2009, 23(3):196-210.
17. Hobbs FDR, Gensini G, Mancini GBJ. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009, 16(4):472-480.
18. Julius S, Kjeldsen SE, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363(9426):2022-2031.
19. Sever PS, Dahlöf B, Poulter NR. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361(9364):1149-1158.
20. Colhoun HM, Betteridge DJ, Durrington PN. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364(9435):685-696.
21. LaRosa JC, Grundy SM, Waters DD. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352(14):1425-1435.
22. Dahlöf B, Sever PS, Poulter NR. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366(9489):895-906.
23. Sever PS, Poulter NR, Dahlöf B. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008, 29(4):499-508.
24. Sever PS, Poulter NR, Dahlöf B. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009, 27(5):947-954.
25. Estimate of 10-year risk scores. http://www.nhlbi.nih.gov/guidelines/cholesterol/risk_tbl.htm, Available at: Accessed on 31 March, 2009
26. Wilson PW, D'Agostino RB, Levy D. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
27. Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
29. Agarwal S, Tang SSK, Rosenberg N. Does synchronizing initiation of therapy affect adherence to concomitant use of antihypertensive and lipid-lowering therapy? Am J Ther 2009, 16(2):119-126.
30. Johnson ML, Pietz K, Battleman DS. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care 2006, 44(1):39-46.
31. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157(21):2413-2446.
32. MacDonald TM, Morant SV, Mozaffari E. Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Curr Med Res Opin 2007, 23(11):2765-2774.
33. Preston RA, Harvey P, Herfert O. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J Clin Pharmacol 2007, 47(12):1555-1569.
34. Cardiovascular disease risk reduction, Adult cholesterol guidelines update, ATP IV hypertension guidelines update, JNC 8 obesity guidelines update. http://www.nhlbi.nih.gov/guidelines/cvd_adult/background.htm, Available at: Accessed on March 31, 2009
35. Lagu T, Weiner MG, Hollenbeak CS. The impact of concordant and discordant conditions on the quality of care for hyperlipidemia. J Gen Intern Med 2008, 23(8):1208-1213.
36. Ogden LG, He J, Lydick E. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000, 35(2):539-543.